MedTrace Logo

NGS and TME for Evidence-based Treatment of Pancreatic Cancer

NCT02767700 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2023-10-24

No results posted yet for this study

Summary

The tumor tissue of patients with pancreatic cancer will be submitted to next-generation sequencing (NGS) and these data will be evaluated with an oncology treatment decision support (TDS) software tool that is a medicinal product class 1 (CE-marked). This software will make evidence-based suggestions for drugs likely to be effective, ineffective, or toxic (FDA approved biomarkers). For patients fit for second-line therapy, the resulting recommendations will be judged by the tumor board.

Conditions

Interventions

GENETIC

NGS

Next generation sequencing

Sponsors & Collaborators

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Johan Permert, MD PhD · Karolinska University Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-03-25
Completion
2018-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02767700 on ClinicalTrials.gov